Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-III

Inclusion Criteria: * Male or female patients between 18 and 65 years (both inclusive) * Patients with positive RT-PCR test for SARS-CoV-2 in nasopharyngeal or oropharyngeal swabs (sample collected or proof of positive test ≤3 days before randomization) * Patients with mild COVID-19 have the following symptoms and signs prior to randomization (≤ 3days) * Upper respiratory tract symptoms (\&/or fever) without shortness of breath or hypoxia. (SpO2 \> 94 %) * Willingness to sign written informed consent document Exclusion Criteria: * \< 18 years of age * Hospitalized patients * Subject with known allergy or hypersensitivity to the components of the formulation. * Patients receiving therapy with Monoamine oxidase inhibitors (MAOIs): rasagline, selegiline, isocarbonboxasid, phenelzine, tranylcypromine. * Patients with narrow-angle glaucoma * urinary retention * Sleep Apnea * History of immunodeficiency or receiving immunosuppressive therapy. * Patients with acute exacerbation of severe comorbidities such as chronic obstructive pulmonary disease (COPD), class 3 and 4 heart failure diagnosed according to the criteria of the New York Heart Failure Association (NYHA), or diseases with severe oxygenation problems * Any Surgical procedure in the past 12 weeks * Unable to make informed consent or refuse or renounce adherence to standard treatment protocols. * Any significant illness or drugs that could interfere with study parameters * Any other condition based on the investigator's clinical judgment does not justify the patient's participation in the study. * Participation in another clinical trial within the past 30 days * Clinically significant arrhythmia or symptomatic cardiac conditions including but not limited to QT elongation * QT interval less than 300 ms or more than 500 ms for both men and women.